Active Lipid Management In Coronary Artery Disease (ALMICAD) study

Am J Med. 2007 Aug;120(8):734.e11-7. doi: 10.1016/j.amjmed.2006.06.048.

Abstract

Purpose: Many providers have implemented specialized lipid clinics to more effectively identify, monitor, and treat hyperlipidemia in patients with coronary artery disease. The effectiveness of such a strategy is not known. We sought to investigate whether a specialized clinic achieves better lipid results and clinical outcomes than standard care.

Subjects and methods: A total of 1233 patients who had coronary disease documented by coronary angiography were randomized to lipid clinic or standard care groups by their providers and followed for 2 years. The primary end point was a composite of death, myocardial infarction, repeat revascularization, and stroke.

Results: Lipid clinic (n=617) and standard care (n=616) groups had no significant baseline differences. After 2 years, the lipid clinic group had similar total cholesterol (166+/-42 mg/dL vs 166+/-41 mg/dL, P=.83), low-density lipoprotein cholesterol levels (84+/-32 vs 85+/-32, P=.28), and percentage of patients with low-density lipoprotein cholesterol less than 100 mg/dL (77.5% vs 77.6%, P=.97). There were no significant differences in the primary end point (12.3% vs 11.4%, P=.60) and mortality (7.6% vs 7.3%, P=.80) between the lipid clinic and standard care groups.

Conclusions: In patients identified by diagnostic coronary angiography and managed within a single health care system, implementation of a specialized lipid clinic did not achieve greater attainment of hyperlipidemia treatment goals or improved cardiac outcomes.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alanine Transaminase / blood
  • Algorithms
  • Ambulatory Care / methods*
  • Cholesterol / blood
  • Comorbidity
  • Coronary Angiography
  • Coronary Artery Bypass
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / epidemiology*
  • Coronary Artery Disease / mortality
  • Disease-Free Survival
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hyperlipidemias / blood
  • Hyperlipidemias / epidemiology*
  • Hyperlipidemias / therapy*
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology
  • Prospective Studies
  • Single-Blind Method
  • Stroke / epidemiology
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • Cholesterol
  • Alanine Transaminase